Form 4 for KYTX Kyverna Therapeutics, Inc.
Accepted 2025-12-22 00:00:00 ET · period of report 2025-12-18 · accession 0001104659-25-123597 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-12-22 | 2025-12-18 | KYTX | SEIDENBERG BETH C | Dir | P - Purchase | $7.50 | +133.3K | 869.3K | +18% | +$1000.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-18 | P | A | 133,333 | $7.50 | 869,317 | I See Footnote | — | — | (F1) Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any. |